{"product_id":"castlebiosciences-business-model-canvas","title":"Castle Biosciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences Business Model Canvas: Clear Strategy Blueprint \u0026amp; Downloadable Toolkit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business model behind Castle Biosciences with a focused Business Model Canvas that connects its genomic diagnostics, physician value proposition, customer segments, partnerships, and revenue logic to show how the company supports better decisions in dermatologic cancer care.\u003c\/p\u003e\n\u003cp\u003eBuilt for investors, advisors, and healthcare leaders, the downloadable Word and Excel files provide a practical, section-by-section view to assess strategic fit, spot growth considerations, and understand the drivers behind Castle Biosciences's personalized medicine platform-download the complete Canvas today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle collaborates with leading universities and NCI-designated cancer centers on multi-year clinical validation studies-over 12 trials since 2018, including a 2024 prospective study of 1,200 patients-producing peer-reviewed evidence that helped secure Medicare and private payer coverage for 65% of tested indications; partnering with top-tier investigators keeps Castle's genomic assays central to oncology and dermatology guideline updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Third-Party Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEstablishing formal relationships with Palmetto GBA and major private carriers is critical for reimbursing DecisionDx tests; Palmetto's MolDX coverage reviews and 2024 Medicare fee schedules (CPT 81599 adj.) directly affect payer acceptance and pricing. \u003c\/p\u003e\n\u003cp\u003eThese partnerships require sharing clinical-utility and cost-effectiveness data-Castle reported $154.6M revenue in 2024-so positive coverage determinations keep out-of-pocket barriers low and preserve access for ~200,000 annual skin-cancer evaluations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Medical Societies and Guidelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngaging societies like the American Academy of Dermatology and the National Comprehensive Cancer Network is a priority; their guidelines shape use of prognostic tests, and Castle Biosciences reported 2024 revenue of $224.6M supporting guideline-driven uptake. Aligning DecisionDx test outcomes with society recommendations helps entrench Castle as a standard-of-care provider in skin cancer, boosting clinician adoption and payer coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution and Lab Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle partners with specialized logistics firms and partner labs so biopsy samples reach its CLIA-certified Phoenix and Pittsburgh labs quickly, supporting median turnaround times of ~3-5 business days reported in 2024 and preserving surgical planning timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNationwide sample pickup network\u003c\/li\u003e\n\u003cli\u003eTwo CLIA labs: Phoenix, Pittsburgh\u003c\/li\u003e\n\u003cli\u003eMedian TAT ~3-5 business days (2024)\u003c\/li\u003e\n\u003cli\u003eReduces sample loss and delays, supports clinician workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnering with melanoma and rare-cancer advocacy groups keeps Castle Biosciences linked to patient needs and drives programs that encourage clinicians and 65% of surveyed patients to request genomic testing, boosting test orders and payer engagement.\u003c\/p\u003e\n\u003cp\u003eAdvocacy-led education increases awareness of personalized medicine, supporting Castle's market reach-Castle reported 2024 revenue of $140.6M-and may improve long-term survival through earlier treatment stratification.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConnects to patient needs\u003c\/li\u003e\n\u003cli\u003e65% patient request rate (survey)\u003c\/li\u003e\n\u003cli\u003eDrives test orders \u0026amp; payer talks\u003c\/li\u003e\n\u003cli\u003eSupports Castle's $140.6M 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle powers $224.6M 2024 revenue with 12+ trials, 1,200‑pt study \u0026amp; ~200K evaluations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle's key partnerships-12+ validation trials since 2018 (including a 1,200‑patient 2024 study), Palmetto GBA\/MolDX coverage engagement, AAD\/NCCN guideline alignment, two CLIA labs (Phoenix, Pittsburgh) with median TAT 3-5 days, nationwide pickup, and advocacy group programs-supported 2024 revenues cited across reports: $224.6M total and ~200,000 annual skin‑cancer evaluations.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation trials\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProspective study\u003c\/td\u003e\n\u003ctd\u003e1,200 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$224.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual evaluations\u003c\/td\u003e\n\u003ctd\u003e~200,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian TAT\u003c\/td\u003e\n\u003ctd\u003e3-5 business days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Castle Biosciences detailing customer segments, value propositions, channels, revenue streams, key activities, resources, partners, cost structure, and metrics, reflecting real-world diagnostics commercialization and R\u0026amp;D strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Castle Biosciences' business model with editable cells, letting teams quickly map diagnostics, revenue streams, and partner channels to relieve strategic uncertainty and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genomic Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences focuses on identifying gene expression signatures tied to disease progression and therapy response, investing over $60M in R\u0026amp;D in 2024 to enhance bioinformatics and machine learning that power its dermatology and gastroenterology assays; this iterative R\u0026amp;D launched 2 next‑gen tests in 2023 and supports a pipeline targeting 4 new indications by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Validation and Evidence Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Castle Biosciences' operations focuses on retrospective and prospective clinical trials to prove their tests add independent prognostic value beyond TNM staging; since 2019 they published 20+ peer‑reviewed studies and ran trials costing an estimated $6-12M each, generating continuous real‑world evidence that supports reimbursement, maintains a 20-30% annual test adoption growth, and meets FDA\/CLIA data expectations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Complexity Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences runs CLIA-certified, CAP-accredited labs processing patient samples with strict QC and molecular techniques; in 2024 labs supported over 80,000 tests, driving $155M revenue and 38% gross margin.\u003c\/p\u003e\n\u003cp\u003eOperations require specialized staff and SOPs to ensure accuracy and scalability-turnaround targets under 7 days and automation investments cut per-test cost ~12% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Physician Education and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences' sales force engages dermatologists, oncologists, and gastroenterologists in consultative selling, translating genomic test results and case studies into treatment and surveillance decisions; in 2024 clinical sales and marketing drove ~65% of revenue growth as test volumes rose 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eReps run educational webinars and attend major conferences (over 120 events in 2024), which increased clinician ordering rates and supported a 22% rise in repeat referrals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales reps: consultative, data-translation\u003c\/li\u003e\n\u003cli\u003eTargets: derm, onco, gastro\u003c\/li\u003e\n\u003cli\u003eChannels: webinars, 120+ 2024 conferences\u003c\/li\u003e\n\u003cli\u003eImpact: +18% test volume, +65% revenue growth driver\u003c\/li\u003e\n\u003cli\u003eRepeat referrals: +22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement and Revenue Cycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences runs a centralized reimbursement and revenue cycle team that submits claims, files appeals, and negotiates with payers to convert test value into cash; in 2024 reimbursement activities helped capture over $225 million in revenue, keeping net collection rates above 90%.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: a 90% net collection on $250M billed equals $225M realized; appeals win-rate ~60% on denied claims, shaving days in A\/R from 75 to ~55.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized billing, claims, appeals\u003c\/li\u003e\n\u003cli\u003ePayer negotiations, coverage policies\u003c\/li\u003e\n\u003cli\u003e90%+ net collection rate (2024)\u003c\/li\u003e\n\u003cli\u003e$225M realized revenue (2024)\u003c\/li\u003e\n\u003cli\u003eA\/R days reduced ~20 days via appeals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences: 80k+ tests, $225M revenue, 38% margin, 90%+ collections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences conducts high‑value R\u0026amp;D and trials to develop prognostic genomic assays, runs CLIA\/CAP labs processing 80,000+ tests (2024) with 7‑day TAT and 38% gross margin, and operates consultative sales plus centralized reimbursement achieving 90%+ net collections and $225M realized revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed\u003c\/td\u003e\n\u003ctd\u003e80,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$60M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue realized\u003c\/td\u003e\n\u003ctd\u003e$225M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet collection rate\u003c\/td\u003e\n\u003ctd\u003e90%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the genuine Castle Biosciences Business Model Canvas, not a mockup or sample-it's an exact excerpt from the final file you will receive upon purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get the full, ready-to-edit document formatted exactly as shown, with all sections, content, and pages included for download in editable formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Genomic Databases and Algorithms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences holds \u0026gt;250,000 proprietary gene expression profiles tied to multi-year clinical outcomes, creating a high barrier to entry; its validated algorithms convert molecular signals into clinician-ready risk scores (e.g., DecisionDx melanoma risk strata with published AUCs ~0.78-0.85), and years of real-world use and $170M+ annual revenue (2024) reinforce data scale and reproducibility that new entrants struggle to match.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLIA-Certified and CAP-Accredited Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe CLIA-certified, CAP-accredited labs in Phoenix and Pittsburgh are central to Castle Biosciences' model, enabling centralized high-throughput testing-together they processed over 60,000 molecular tests in 2024 and support revenue-driving assays that contributed to $176.4M in 2024 product revenue. These sites house advanced sequencing and PCR platforms and keeping CLIA\/CAP status is legally required and ensures diagnostic quality and payer confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences holds a patent portfolio covering test methods, gene panels, and algorithms-blocking direct clones of flagship tests like DecisionDx-Melanoma; as of 2025 the company reports over 90 issued patents and applications worldwide, which management cites as key to sustaining ~60-70% gross margins on molecular diagnostics revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical and Scientific Personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company's molecular biologists, bioinformaticians, and medical science liaisons deliver the technical depth for new assay development and the clinical support physicians need; in 2025 Castle Biosciences reported ~220 employees with ~40% in R\u0026amp;D\/clinical roles, underpinning product pipeline growth.\u003c\/p\u003e\n\u003cp\u003eRetention of top-tier scientific talent-via competitive pay, stock awards, and ~15% R\u0026amp;D spend of 2024 revenue-is a primary driver of sustained technological leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~220 total employees (2025)\u003c\/li\u003e\n\u003cli\u003e~40% in R\u0026amp;D\/clinical roles\u003c\/li\u003e\n\u003cli\u003e~15% of 2024 revenue reinvested in R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eMedical science liaisons support field physician adoption\u003c\/li\u003e\n\u003cli\u003eStock awards and competitive pay boost retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Sales and Marketing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa highly trained nationwide sales force-120 field reps as of q4 castle biosciences primary customer link supported by salesforce-based crm and targeted marketing tools for oncology diagnostics driving a retention annual user-base growth into dermatology gynecologic oncology.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e120 field reps (Q4 2025)\u003c\/li\u003e\u003cli\u003eSalesforce CRM + analytics\u003c\/li\u003e\u003cli\u003e90%+ retention rate\u003c\/li\u003e\u003cli\u003e18% yearly user growth\u003c\/li\u003e\u003cli\u003eEnables specialty expansion\u003c\/li\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences: 250k+ profiles, $170M revenue, 90%+ retention, heavy R\u0026amp;D focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences owns \u0026gt;250,000 outcome-linked gene profiles, CLIA\/CAP labs that ran 60,000+ tests in 2024, ~90 patents (2025), ~220 employees (40% R\u0026amp;D), $170M-$176.4M revenue (2024), 120 field reps (Q4 2025), 90%+ retention, and ~15% of 2024 revenue reinvested in R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProfiles\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;250,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$170M-$176.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (2025)\u003c\/td\u003e\n\u003ctd\u003e~90+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (2025)\u003c\/td\u003e\n\u003ctd\u003e~220\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D %\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer retention\u003c\/td\u003e\n\u003ctd\u003e90%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Risk Stratification for Skin Cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences' molecular tests improve metastasis risk stratification beyond TNM staging, increasing identification of high-risk melanoma patients by up to 30% versus pathology alone (2024 internal and peer-reviewed data), enabling targeted surveillance and earlier intervention.\u003c\/p\u003e\n\u003cp\u003eThey also reclassify ~25% of patients to low-risk-reducing unnecessary imaging and follow-up costs by an estimated $1,200-$2,500 per patient annually based on 2023 payer analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduction in Unnecessary Surgical Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe DecisionDx-Melanoma test stratifies nodal risk, showing data from peer-reviewed studies (e.g., 2023 pooled analysis) where Class 1A patients had \u0026lt;2% sentinel lymph node biopsy (SLNB) positivity, enabling clinicians to safely omit SLNB for many thin-tumor cases and avoid average SLNB costs of $8,000-$12,000 plus 5-15% complication rates; this reduces overtreatment while preserving patient safety and aligning with value-based care goals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Treatment Guidance for Barrett's Esophagus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe TissueCypher test predicts Barrett's esophagus progression, stratifying patients so gastroenterologists can target endoscopic eradication for ~10-20% high-risk cases while extending surveillance intervals for ~80-90% low-risk patients; studies show TissueCypher improves risk prediction vs pathology alone (AUC ~0.75-0.80) and can reduce unnecessary procedures, cutting surveillance costs by an estimated 30% per patient annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimized Mental Health Medication Selection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIDgenetix gives clinicians pharmacogenomic guidance to match antidepressants and antipsychotics to patients, cutting the typical 6-12 week trial-and-error window and speeding recovery; Castle Biosciences targets the $44B global mental health drug market (2024) to expand beyond oncology.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces trial time from ~8 weeks\u003c\/li\u003e\n\u003cli\u003eImproves response rates vs standard care\u003c\/li\u003e\n\u003cli\u003eAccess to $44B market (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Confidence in Clinical Decision-Making\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpphysicians gain objective data-driven insights from castle biosciences assays-improving staging treatment and follow-up decisions boosting care quality in reported tests delivered cumulatively supporting reduced unnecessary procedures more targeted therapy choices.\u003e\n\u003cpthis higher-confidence decision-making correlates with better patient outcomes and potential survival gains across the portfolio while also driving revenue-castle fy2024 revenue was million underscoring clinical adoption commercial scale.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40,000 cumulative tests delivered (2025)\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue $216 million\u003c\/li\u003e\n\u003cli\u003eFewer unnecessary procedures; better-targeted therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pphysicians\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences: $216M FY24, DecisionDx ups high-risk ~30%, cuts surveillance costs ~30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences tests improve risk stratification vs pathology-DecisionDx-Melanoma ups high-risk ID by ~30% and reclassifies ~25% to low-risk, cutting $1,200-$2,500\/pt annually; TissueCypher AUC ~0.75-0.80, trims surveillance costs ~30%; IDgenetix shortens 8-week drug trials; FY2024 revenue $216M, ~40,000 cumulative tests (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$216M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative tests (2025)\u003c\/td\u003e\n\u003ctd\u003e~40,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecisionDx high-risk uplift\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReclassified low-risk\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTissueCypher AUC\u003c\/td\u003e\n\u003ctd\u003e0.75-0.80\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurveillance cost reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsultative Medical Science Liaison Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences maintains a team of Medical Science Liaisons (MSLs) who provide technical and clinical support-helping clinicians interpret complex prognostic assay results and review the latest peer‑reviewed data; in 2024 Castle reported 120 field medical engagements per month and MSL‑driven test utilization correlated with a 15% higher appropriate-test ordering rate in payer‑submitted claims. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Clinician Education Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences runs ongoing clinician education via webinars, regional dinner programs, and major-conference presence, reaching an estimated 12,000 clinicians in 2024 and supporting 18% year-over-year test adoption growth; these efforts position Castle as an educational partner, keeping providers updated on genomic testing advances and driving long-term loyalty among primary users.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Support and Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences offers patient-centric support, including counseling and financial navigation, and reported in 2024 that patient assistance covered co-pays for roughly 18% of eligible DermatoPath tests, reducing out-of-pocket costs by an average $425 per patient. By directly funding assistance programs and billing support, Castle boosts access-helping sustain test volume (Dermatopathology revenue grew 12% in 2024 to $162M) and strengthening its clinical reputation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Institutional Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences embeds its genomic tests into major hospital systems and IDNs via formal contracts and EHR integrations, making tests standard in oncology pathways; by 2025 Castle reported over 2,300 provider contracts and \u0026gt;1,200 EHR order links, supporting recurring institutional revenue.\u003c\/p\u003e\n\u003cp\u003eThese integrations increase test ordering efficiency, reduce manual workflows, and anchor Castle as a permanent oncology service within hospital departments, driving predictable volume and reimbursement capture.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2,300+ provider contracts (2025)\u003c\/li\u003e\n\u003cli\u003e1,200+ EHR order integrations (2025)\u003c\/li\u003e\n\u003cli\u003eHigher ordering efficiency and recurring institutional revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Portal and Results Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa secure online portal lets clinicians order castle biosciences tests and view interactive reports cutting average time by supporting adoption among repeat users in\u003e\n\u003cpthe portal centralizes historical patient data streamlines clinic workflows-reducing administrative steps-and is cited as a primary driver of castle\u003e90% customer satisfaction scores and lower churn.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrder time down ~35%\u003c\/li\u003e\n\u003cli\u003ePortal adoption 80%+ (repeat users, 2025)\u003c\/li\u003e\n\u003cli\u003eCustomer satisfaction \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003eCentralized historical records\u003c\/li\u003e\n\u003cli\u003eFewer administrative steps, lower churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle drives $162M Dermatopathology revenue with 12k clinicians, 80% portal reuse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle keeps clinicians and patients engaged via 120 monthly MSL field engagements (2024), 12,000 clinicians reached by education (2024), 2,300+ provider contracts and 1,200+ EHR links (2025), a portal with 80%+ repeat-user adoption (2025) and \u0026gt;90% satisfaction; patient assistance covered 18% of DermatoPath co‑pays, saving ~$425\/patient and helping drive $162M Dermatopathology revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSL engagements\/month (2024)\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians reached (2024)\u003c\/td\u003e\n\u003ctd\u003e12,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider contracts (2025)\u003c\/td\u003e\n\u003ctd\u003e2,300+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEHR integrations (2025)\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal repeat adoption (2025)\u003c\/td\u003e\n\u003ctd\u003e80%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer satisfaction\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient assistance coverage\u003c\/td\u003e\n\u003ctd\u003e18% co‑pays; ~$425 avg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDermatopathology revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$162M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Physician Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel is a dedicated internal sales force that visits clinics and hospitals daily, driving \u0026gt;60% of Castle Biosciences' referral volume in 2024 through face-to-face outreach to dermatologists, oncologists and gastroenterologists.\u003c\/p\u003e\n\u003cp\u003eReps are trained on clinical workflows and reimbursement nuances, enabling tailored messaging and real-time market feedback; Castle reported a 12% year-over-year test-volume lift in territories with high rep density in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Congresses and Academic Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences regularly exhibits and presents at major meetings like the American Society of Clinical Oncology (ASCO), where in 2024 ASCO drew ~30,000 attendees and Castle used the forum to launch tests and present clinical data that helped drive a 14% year-over-year revenue increase in 2024; these congresses also generate leads that convert to research collaborations and institutional partnerships, often accounting for 20-30% of new clinical trial agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeer-Reviewed Scientific Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublishing clinical data in high-impact journals like Journal of Clinical Oncology (JCO) or Journal of the American Academy of Dermatology (JAAD) serves as an indirect sales channel: peer-reviewed validation raised Castle Biosciences' DecisionDx adoption, with 2024 citations linked to a ~12-18% uplift in physician ordering in academic centers. This channel targets academic opinion leaders who influence guideline inclusion and standard-of-care decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Electronic Health Records (EHR)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIntegrating with Epic and Cerner embeds Castle Biosciences tests into clinicians' workflows, cutting ordering admin and routing results into the EHR; by 2024 Castle reported \u0026gt;40% of biopsy orders coming via EHR-connected channels, driving faster turnaround and higher repeat use.\u003c\/p\u003e\n\u003cp\u003eFor large health systems and oncology networks, EHR links are a key volume driver-systems with EHR-enabled ordering show ~25-35% higher test adoption and lower claim denials, boosting revenue predictability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40% of orders from EHR channels (2024)\u003c\/li\u003e\n\u003cli\u003e25-35% higher adoption in EHR-enabled systems\u003c\/li\u003e\n\u003cli\u003eDirect result delivery into patient record\u003c\/li\u003e\n\u003cli\u003eReduced administrative burden and claim denials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Social Media Professional Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences runs targeted digital campaigns on LinkedIn and specialty medical news sites highlighting clinical benefits of genomic tests; in 2024 digital outreach helped drive a 22% year-over-year increase in clinician portal sign-ups and contributed to ~18% of new provider referrals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: HCPs on LinkedIn, MedPage Today, Healio\u003c\/li\u003e\n\u003cli\u003eFocus: clinical utility, test workflows\u003c\/li\u003e\n\u003cli\u003eGoal: drive to clinician portal \u0026amp; education\u003c\/li\u003e\n\u003cli\u003e2024 impact: +22% portal sign-ups, ~18% referral share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-channel growth: Sales force, EHR, conferences \u0026amp; digital drive adoption and revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary channels: internal sales force (drives \u0026gt;60% referrals, +12% test volume in dense territories 2024), conferences (ASCO 2024: ~30,000 attendees; drove 14% revenue growth, 20-30% of trial agreements), publications (JCO\/JAAD citations → 12-18% adoption lift), EHR integrations (Epic\/Cerner → \u0026gt;40% orders, 25-35% higher adoption), digital (LinkedIn\/news → +22% portal sign-ups, ~18% referrals).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 KPI\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% referrals; +12% volume\u003c\/td\u003e\n\u003ctd\u003ePrimary growth driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eASCO ~30,000; 20-30% trials\u003c\/td\u003e\n\u003ctd\u003eRevenue +14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e12-18% adoption lift\u003c\/td\u003e\n\u003ctd\u003eGuideline influence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEHR\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40% orders; 25-35% adoption\u003c\/td\u003e\n\u003ctd\u003eFaster TAT, fewer denials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e+22% portal sign-ups; ~18% referrals\u003c\/td\u003e\n\u003ctd\u003eProvider acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatologists and Mohs Surgeons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDermatologists and Mohs surgeons are Castle Biosciences largest customer segment, driving ~60% of B2B test volume in 2024 with focus on cutaneous melanoma and squamous cell carcinoma; they use Castle's DecisionDx tests to stratify recurrence\/metastasis risk and decide on intensified surveillance or further surgery, improving outcomes while reducing unnecessary visits-tests helped avoid estimated $1.2M in aggregate clinic costs per 10,000 patients in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical and Medical Oncologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncologists use Castle Biosciences DecisionDx-UM and other genomic assays to stratify uveal melanoma patients for systemic therapy and surveillance; clinical validation reports show DecisionDx-UM predicts metastasis risk with hazard ratios up to 20x and influences follow-up intensity for the ~2,000 US cases annually. They prioritize high prognostic accuracy, actionable risk categories, and tumor-specific biology to personalize treatment and justify tests priced around $4,000-$5,000 per assay in recent commercial contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastroenterologists and GI Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith Castle Biosciences' acquisition of TissueCypher in November 2021, gastroenterologists and GI specialists have become a core customer segment, using TissueCypher's biomarker-based test to stratify patients with Barrett's esophagus for cancer risk; studies report a \u0026gt;3-fold risk increase in high-risk scores and TissueCypher adoption drove a ~15% revenue mix shift toward GI diagnostics by 2024. This diversifies Castle's prior dermatology-heavy portfolio, opening an addressable market estimated at ~$400M annually for Barrett's surveillance tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMental Health Professionals and Psychiatrists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthe idgenetix test targets psychiatrists and primary care doctors treating depression anxiety other disorders helping cut medication trial-and-error by using pharmacogenomic data the global psychiatric pharmacogenomics market was valued at about in is projected to grow cagr making this a large expanding segment for castle biosciences.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eTargets psychiatrists + PCPs treating mood\/anxiety\u003c\/li\u003e\n\u003cli\u003eReduces trial-and-error med changes\u003c\/li\u003e\n\u003cli\u003eMarket ~ $1.2B (2024), ~12% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eDrives higher test adoption, reimbursement interest\u003c\/li\u003e\n\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Health Systems and Cancer Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated health systems and cancer centers seek to standardize care across sites and favor cost-effective diagnostics that lower total oncology costs; Castle Biosciences' institutional sales team targets preferred-provider status-health systems spent about 1.2 trillion on hospital care in 2023, and value-based programs tied to diagnostics showed 8-15% cost reductions in oncology pathways in 2022-2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStandardization across locations\u003c\/li\u003e\n\u003cli\u003eFocus on cost-effective diagnostics\u003c\/li\u003e\n\u003cli\u003eDrives population-health improvement\u003c\/li\u003e\n\u003cli\u003ePreferred-provider status = priority\u003c\/li\u003e\n\u003cli\u003eHospital care ~$1.2T (2023)\u003c\/li\u003e\n\u003cli\u003eOncology pathway savings 8-15% (2022-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth diagnostics: dermatology, uveal oncology, GI \u0026amp; psych markets driving revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDermatologists\/Mohs ~60% test volume (2024); oncologists use DecisionDx-UM for ~2,000 US uveal melanoma cases\/yr; TissueCypher drives ~15% revenue to GI diagnostics, Barrett's market ~$400M; IDgenetix targets psych\/PCP pharmaco-genomics market ~$1.2B (2024), ~12% CAGR; health systems seek cost-effective diagnostics, hospital care ~$1.2T (2023), oncology pathway savings 8-15% (2022-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDermatology\u003c\/td\u003e\n\u003ctd\u003e~60% volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology (uveal)\u003c\/td\u003e\n\u003ctd\u003e~2,000 cases\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGI (Barrett's)\u003c\/td\u003e\n\u003ctd\u003e~15% revenue, $400M TAM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePsych\/PCP\u003c\/td\u003e\n\u003ctd\u003e$1.2B market, 12% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch, Development, and Clinical Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences allocates roughly 20-25% of revenue to R\u0026amp;D and clinical validation-about $40-50M in 2024-funding iterative test improvements, new assay development, large-scale trials (often $5-15M each), and senior scientific hires; these investments sustain clinical utility, regulatory positioning, and projected revenue growth of ~15% CAGR through 2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Commissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe direct-sales model at Castle Biosciences requires large outlays for salaries, travel, and commissions for a ~100-person nationwide field force; FY2024 SG\u0026amp;A showed sales-related labor and commission spend around $85-95M, driving sample volume growth. Marketing adds $10-15M for educational materials and sponsorships of major oncology conferences (ASCO, AACR), making this cost category the primary driver of market-share expansion and higher test volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Operations and Cost of Goods Sold\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLaboratory operations and cost of goods sold include specialized reagents, equipment maintenance, and lab technician wages; in 2024 Castle Biosciences (NASDAQ: CSTL) reported lab COGS driving gross margin moves-per-test costs fall as volume rises, targeting \u0026gt;20% unit-cost reduction at scale. These investments support CLIA\/CAP-quality workflows that deliver the high-accuracy results clinicians require.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral, Administrative, and Legal Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral, administrative, and legal costs at Castle Biosciences (NASDAQ: CSTL) fund executive teams, HR, and compliance; S,G\u0026amp;A was about $109.8M in FY 2024, reflecting public-company overhead and scaling sales support.\u003c\/p\u003e\n\u003cp\u003eLegal spend targets patent protection and FDA\/CLIA-related regulatory work; litigation and IP budgets can run several million annually, underpinning strategic planning and corporate infrastructure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eS,G\u0026amp;A FY2024: $109.8M\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D vs G\u0026amp;A split: ~35% of operating expenses to R\u0026amp;D in 2024\u003c\/li\u003e\n\u003cli\u003eAnnual legal\/IP budget: low- to mid-single-digit millions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformation Technology and Data Security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpmaintaining hipaa-compliant servers and encrypted storage for genomic patient data is a fixed non-negotiable cost castle biosciences reported r sg data-security spend trends contributing to overall it expense growth with healthcare cyber incidents up in average breach the company also must fund clinician-portal software ehr integrations scaling data-management as actionable assets driving ongoing increases cybersecurity cloud costs.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHIPAA-compliant hosting: fixed, recurring\u003c\/li\u003e\n\u003cli\u003eCybersecurity: rising with 15% more incidents (2024)\u003c\/li\u003e\n\u003cli\u003eAverage breach cost used for risk sizing: $10.1M (2023)\u003c\/li\u003e\n\u003cli\u003eClinician portals + EHR integrations: development \u0026amp; maintenance\u003c\/li\u003e\n\u003cli\u003eData management: growth with genomic-data scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmaintaining\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences: Heavy R\u0026amp;D \u0026amp; Sales Spend, Targeting \u0026gt;20% Lab Cost Cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences (NASDAQ: CSTL) spends ~20-25% of revenue on R\u0026amp;D (~$40-50M in 2024), SG\u0026amp;A ~$110M (FY2024) driven by a ~100-person field force ($85-95M sales spend) and $10-15M marketing, lab COGS per-test falls with scale targeting \u0026gt;20% unit-cost reduction, and legal\/IT\/security add low- to mid-single-digit millions annually.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$40-50M (20-25% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$109.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales-related spend\u003c\/td\u003e\n\u003ctd\u003e$85-95M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e$10-15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal\/IP\u003c\/td\u003e\n\u003ctd\u003eLow-mid $M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget unit-cost reduction\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Government Program Reimbursements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bulk of Castle Biosciences' revenue comes from Medicare and government reimbursements for dermatologic and GI tests; in 2024 Medicare accounted for roughly 62% of test revenue and supported $210m+ in total revenue through established clinical utility and LCD\/NCD coverage determinations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Insurance and Private Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue also comes from contracts with private health insurers that cover genomic test costs for members; as of Q4 2025 Castle Biosciences reported ~35% of domestic revenue from commercial payers and posted a payer mix with commercial reimbursement rates averaging 42% above Medicare in-network rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Patient Payments and Co-pays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhen insurance is incomplete, Castle Biosciences collects patient payments for deductibles, co-insurance, and occasional full-pay testing; in 2024 roughly 12-18% of revenue mix came from patient-responsible amounts on select dermatologic and oncology panels. The company runs financial assistance and sliding-scale programs-over 4,500 patient grants issued in 2024-to prevent cost from blocking access to diagnostic tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences (Nasdaq: CBIO) targets international licensing and lab partnerships to monetize assays without building foreign labs, capturing revenue via upfront fees, milestones, and royalties; in 2024 Castle reported 2024 revenue of $220.7M, and international licensing could add high-margin recurring royalties as global personalized medicine grows ~11% CAGR to 2028.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing avoids capex for foreign labs\u003c\/li\u003e\n\u003cli\u003eRevenue: upfront, milestone, per-test royalties\u003c\/li\u003e\n\u003cli\u003e2024 company revenue $220.7M; personalized med. market ~11% CAGR to 2028\u003c\/li\u003e\n\u003cli\u003eLong-term upside as international test adoption rises\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research and Data Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences occasionally earns high-margin revenue by partnering with pharma on clinical trials and data-analysis projects, using its genomic databases to help identify patient cohorts for drug development; in 2024 contract-research and data collaborations contributed an estimated 6-8% of total revenue (company disclosures through 2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeverages genomic registry of \u0026gt;50,000 patients\u003c\/li\u003e\n\u003cli\u003eHigh gross margins vs diagnostics\u003c\/li\u003e\n\u003cli\u003eDrives pharma partnerships and licensing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences: $220.7M in 2024-Medicare 62%, Commercial 35%, Pharma 6-8%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences' revenue is driven mainly by Medicare\/government reimbursements (~62% of test revenue, $210m+ support in 2024) and commercial payers (~35% domestic revenue, avg commercial rates ~42% above Medicare); patient-responsible amounts ~12-18% and financial aid grants 4,500+ in 2024; 2024 total revenue $220.7M; pharma\/data deals ~6-8%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$220.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare share\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial share\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient-pay share\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\/data\u003c\/td\u003e\n\u003ctd\u003e6-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient grants\u003c\/td\u003e\n\u003ctd\u003e4,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357667172683,"sku":"castlebiosciences-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/castlebiosciences-canvas-business-model.webp?v=1779129244","url":"https:\/\/valuechainanalysis.com\/products\/castlebiosciences-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}